Joshua Funder

Joshua Funder joined GBS Partners in 2004 and has more than 17 years of experience in biotechnology research, management and venture investing. Joshua has experience as founder, director and chairman of biotechnology companies in Australia and the US, and brings extensive experience of international venture syndication.

Joshua served as interim CEO of Proacta Inc. following GBS investment and is on the board of directors of GBS portfolio companies Spinifex Pharmaceuticals Pty Ltd, Pathway Therapeutics Inc. and Celladon Corp.

Joshua previously was director of GBS investment company Peplin Inc., which won the AVCAL award for the best early stage investment in 2010.

Before joining GBS, Joshua worked in corporate strategy and development at Infinity Pharmaceuticals in Boston and the Boston Consulting Group in San Francisco. In addition he worked with the Clinton Foundation HIV/AIDS Initiative to successfully negotiate reduced prices for anti-retrovirals and initiate pharmaceutical supplies across eastern and southern Africa.

Joshua earned his Bachelor of Science (Honors) and Bachelor of Laws (Honors) degrees at Melbourne University and his Master of Laws degree at the London School of Economics. Joshua holds a Doctorate of Philosophy in intellectual property for biotechnology from Oxford University where he studied as a Rhodes Scholar.

Joshua Funder is the Member of the Board of Directors at Celladon, based in Australia, Oceania. With a background in Biotechnology, Joshua Funder has a rich history of leadership and innovation. Joshua Funder studied B.Sc. unknown @ University of Melbourne. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.